EFFICACY AND SAFETY OF TUMOUR NECROSIS FACTOR ALPHA INHIBITORS IN RHEUMATOID ARTHRITIS

被引：0

作者：

Baraza Cristina, Gomez ^{[1
]}

Francisco Javier, Manero Ruiz ^{[2
]}

Espasol Angela, Pecondon ^{[2
]}

Mendoza Mercedes, Arenere ^{[3
]}

Orbis Iciar, Casiamares ^{[1
]}

Maria Jose, Rabanaque Hernandez ^{[4
]}

机构：

[1] Hosp Univ Miguel Servet, Dept Pharm, Zaragoza, Spain

[2] Hosp Univ Miguel Servet, Rheumatol Serv, Zaragoza, Spain

[3] Hosp Clin Lozano Blesa, Dept Pharm, Zaragoza, Spain

[4] Univ Zaragoza, Fac Med, Dept Microbiol, Prevent Med & Publ Hlth, Zaragoza, Spain

来源：

ATENCION FARMACEUTICA | 2013年 / 15卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective: To evaluate the efficacy and safety of tumor necrosis factor alpha inhibitors in Rheumatoid Arthritis (RA). Method: An observational and retrospective study conducted on patients with RA treated at a hospital between May 2000 and December 2009. We analyzed the influence of demographic and clinical factors in the effectiveness of treatments and made a comparison between them. We determined the durability of the anti-TNF-alpha agents and adverse reactions. Results: The efficacy study showed improvement in the clinical variables. The survival analysis showed no significant differences depending on the used drug or treatment line. The safety analysis revealed risk of infections. Conclusion: Infliximab, etanercept, and adalimumab are effective drugs for RA therapy, improving symptoms control and showing similar effectiveness between them.

引用

页码：150 / 157

页数：8

共 50 条

[1] TUMOUR NECROSIS FACTOR ALPHA INHIBITORS IN RHEUMATOID ARTHRITIS THERAPY
Laczna, Malgorzata
Tarnowski, Maciej
Kopytko, Patrycja
Bujak, Joanna
Pawlik, Andrzej
[J]. POSTEPY BIOLOGII KOMORKI, 2020, 47 (03) : 247 - 263
[2] Tumour necrosis factor alpha inhibitors for the treatment of adult rheumatoid arthritis
McColl, G.
[J]. AUSTRALIAN PRESCRIBER, 2005, 28 (01) : 6 - 6
[3] Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors
Mewar, Devesh
Wilson, Anthony G.
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2011, 162 (04) : 785 - 791
[4] The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis
Victoria Hernandez, Maria
Sanmarti, Raimon
Canete, Juan D.
[J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 (05) : 613 - 624
[5] EFFICACY AND SAFETY OF LEFLUNOMIDE OR METHOTREXATE PLUS SUBCUTANEOUS TUMOUR NECROSIS FACTOR-ALPHA BLOCKING AGENTS IN RHEUMATOID ARTHRITIS
Benucci, M.
Saviola, G.
Baiardi, P.
Manfredi, M.
Sarzi-Puttini, P.
Atzeni, F.
[J]. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2011, 24 (01) : 269 - 274
[6] The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference
Conti, Fabrizio
Atzeni, Fabiola
Massaro, Laura
Gerardi, Maria Chiara
Gremese, Elisa
Passiu, Giuseppe
Carletto, Antonio
Malavolta, Nazzarena
Foti, Rosario
Ramonda, Roberta
Sarzi-Puttini, Piercarlo
[J]. RHEUMATOLOGY, 2018, 57 : 11 - 22
[7] Tumour Necrosis Factor-α Antagonists in the Management of Rheumatoid Arthritis in the ElderlyA Review of Their Efficacy and Safety
Beáta J. Radovits
Wietske Kievit
Roland F. J. M. Laan
[J]. Drugs & Aging, 2009, 26 : 647 - 664
[8] Tumour Necrosis Factor-α Antagonists in the Management of Rheumatoid Arthritis in the Elderly A Review of Their Efficacy and Safety
Radovits, Beata J.
Kievit, Wietske
Laan, Roland F. J. M.
[J]. DRUGS & AGING, 2009, 26 (08) : 647 - 664
[9] Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis
Roberts, L
McColl, GJ
[J]. INTERNAL MEDICINE JOURNAL, 2004, 34 (12) : 687 - 693
[10] Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis
Katikireddi, Veera S.
Whittle, Samuel L.
Hill, Catherine L.
[J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2010, 13 (01) : 12 - 26

← 1 2 3 4 5 →